Orthotopic liver transplantation (OLT) is the only treatment for end-stage liver failure; however, graft shortage impedes its applicability. Therefore, studies investigating alternative therapies are plenty. Nevertheless, no study has comprehensively analyzed these therapies from different perspectives.
INTRODUCTION
Liver diseases lead the causes of mortality worldwide, accounting for approximately 1-2 million deaths per annum according to the World Health Organization [1] . Orthotopic liver transplantation (OLT) remains as the only curative therapy for endstage liver diseases. However, the shortage of donor organs limits its application.
Alternatives to OLT such as liver support systems, including bioartificial livers, and hepatocyte transplantation have been extensively explored; however, none could be adopted in clinical practice [2] . Thus, to overcome the organ shortage, many researchers attempted to find alternatives to the traditional solid-organ transplantation method [3] .
Various alternative treatments are available, including organ transplantations from other human beings, transplanting cells from other species, or transplanting processed cells from humans or transplanting processed cells from other species.
Alternative therapies investigated in the past include xenotransplantation, scaffoldbased transplantation, and cell transplantation therapies. In particular, the use of animal livers for human patients, i.e., xenotransplantation, has been deemed as a solution for donor shortage. If the organ of other species could be transplanted, there are many advantages about the supply of organ [4] . Although this approach has still several problems, such as immune rejection and coagulopathy, α-1,3galactosyltransferase gene-knockout (GT-KO) pigs that do not express the α1,3Gal (Gal) antigens have improved the potential of this therapy [5, 6] . In fact, it underwent many advancements through genome editing technologies [7] .
Scaffold-based transplantation is a novel method, which aims to generate tissues and organs ex vivo or in vivo with biological materials that can be used to repair, regenerate, or even replace malfunctioning tissues and organs. Essentially, to create scaffolds, all the cells from animal organs are removed while retaining the structural, mechanical, and chemical attributes of the native tissue [8] . Then, the human-derived cells are embedded in the scaffold that serves as an ideal container to generate humanized organs. In parallel, cell transplantation research has undergone vast advancements with the establishment of induced pluripotent stem cells (iPSCs). Clinical human-to-human hepatocyte transplantation following host conditioning has been reported [9] . However, hepatocytes have limitations with respect to proliferation, function, and immunity. Recently, pluripotent or somatic stem cells were used as new sources in place of hepatocytes [10] . Further, researchers tried to direct pluripotent or somatic stem cells toward differentiation into hepatocytes in various studies [11] .
Thus, alternative therapies manifest various combinations depending on different resources. Still, no study has comprehensively analyzed these different viewpoints yet, although such studies are instrumental while considering novel alternatives for the future regarding the utility of these kinds of treatments.
Therefore, we aimed to discuss the current status of alternative transplantation therapies to replace liver organ transplantation and to support their research and development.
MATERIALS AND METHODS
The methodological approach included the development of selection criteria, defining the search strategies, assessing the study quality, and abstracting the relevant data. The PRISMA statements checklist for reporting a systematic review was followed [12] .
Identification and selection of the studies
This systematic literature review was performed to select articles discussing alternatives to liver organ transplantation. The PubMed, Cochrane Library, and EMBASE were electronically searched for articles published between January 2010 and December 2018, using the following MeSH terms: [(liver transplantation) AND cell] OR [(liver transplantation) AND differentiation] OR [(liver transplantation) AND organoid] OR [(liver transplantation) AND xenotransplantation].
Inclusion and exclusion criteria
The study selection criteria were defined before initiating data collection to identify eligible studies for the analysis. Only studies written in English were selected. We retrieved all studies in which the primary objective was to evaluate new transplantation therapies in place of OLT for our analysis.
Exclusion criteria were as follows: (1) 
Study selection and quality assessment
The titles and abstracts of the retrieved studies were independently and blindly screened for relevance by two reviewers (Furuta T and Furuya K), who assessed the study quality and extracted data. To enhance sensitivity, records were removed only in case both reviewers judged them to be inappropriate. All disagreements were resolved by discussion and consensus. The study design, quality, level of evidence, and the relevance of the studies were analyzed according to the objective of this study. 
Treatment modalities and clinical application
From our qualitative analysis on the selected articles, there were 14 xeno-organ transplantation studies, 22 scaffold-based transplantation studies, and 53 cell transplantation studies. The study selection is displayed in Tables 1-3 [2, 5, . There were various sources of alternative therapy, including organ liver (25 studies), adult hepatocytes (31 studies), fetal hepatocytes (three studies), mesenchymal stem cells (MSCs; 25 studies), embryonic stem cells (ESCs; one study), and iPSCs (three studies) and others (Table 4) [2, 5, . Clinical application was discussed in 12 studies. In particular, hepatocyte transplantation was discussed in four studies, umbilical cord derived MSCs (UC-MSCs) transplantation was described in five studies, bone marrow derived MSCs (BM-MSCs) was described three studies and hematopoietic stem cells was described two studies.
DISCUSSION
Among various alternative OLT therapies, only cell transplantation has been adopted in clinical practice. However, its long-term improvement effects are yet to be proven. In particular, few studies report that it can become a bridge for OLT. Considering the viewpoint of cell transplantation, cell processing strategies such as proliferation or hepatic differentiation might assume paramount significance. On the other hand, although scaffold-based transplantation is far from being applied clinically, it is deemed as attractive and promising. This approach has been devised as a treatment method that combines the efficiency of solid organ transplantation with the control of rejection. It is also a comprehensive treatment incorporating cell processing technologies.
Although many patients die from liver failure, there is no other curative treatment other than OLT. However, organ shortage remains as the major shortcoming for transplantation globally. Because of graft shortages, alternative treatments for OLT have received significant research attention.
The concept of scaffold-based transplantation was developed to substitute for the damaged human liver requiring immediate transplantation. In particular, many studies discussed xeno-organ transplantation using decellularized liver scaffolds from other species embedded with human derived hepatic cells.
Our search revealed articles on xeno-organ transplantation (n = 14), scaffold-based transplantation (n = 22), and cell transplantation (n = 53), with the majority being related to "cell therapy".
Cell transplantation
Cell transplantation is an attractive alternative to conventional organ transplantation. Hepatocyte transplantation has also been applied clinically, however, with limited effect. To obtain better transplantation efficiency, studies were conducted to evaluate the differentiation quality and administration methods.
In this study, regarding transplantation cell sources, we found that adult hepatocytes, fetal hepatocytes, stem cells such as iPSCs, ESCs, MSCs, and differentiated hepatocytes-like cells (HLCs) have been used and most report used hepatocytes as the cell source. In addition, our article showed that only cell transplantation was clinically applied.
Lee et al [13] reported the application of neonatal hepatocytes encapsulated in alginate microbeads transplanted in three patients with acute liver failure from error of sulfite metabolism. Hansel et al [100] reported hepatocyte transplantation applied in 100 Hepatocytes Human -Human (ALF) Hepatic function 2018 [13] -Human (ACLF) Hepatic function 2014 [22] -Human ( -Mouse (SCID/Alb-uPA) Analysis of NK cell 2010 [28] UC-MSC (human) Mouse (BALB/c) Engraftment, hepatic function 2018 [29] Rat -Mouse (C57BL/6 FRG) 2018 [30] -Rat (Wistar) Engraftment 2015 [31] -Rat (SD) Engraftment, hepatic function 2015 [32] - -Rat (SD) Hepatic function 2010 [37] Mouse Organoid Mouse (C57BL/6) Engraftment 2017 [38] -Mouse (emdr2 −/− ) Engraftment, Repopulation 2015 [39] -Mouse (Fah-/-) Hepatic function 2010 [40] -Mouse (FVB/N) Engraftment, analysis of metabolite 2010 [41] -Mouse (C57BL/6) Engraftment 2010 [42] Hepatocytes (fetal) Rat -Rat (DPPIV -) Engraftment, repopulation 2018 [43] Mouse -Mouse (C57BL/6) Engraftment, hepatic function 2012 [44] Liver cells Rabbit -Rabbit (New Zealand) Hepatic function 2012 [45] Hepatic oval cells Rat -Rat (Lewis) Hepatic function, survival extension 2013 [46] Hepatoma cell line -Rat (SD) Hepatic function, survival extension 2013 [47] UC-MSCs Human -Human after OLT Hepatic function, intervention rate 2017 [48] -Human after OLT Hepatic function 2017 [49] BM-MSCs/BM-MNCs Human -Human (LC) Hepatic function 2017 [50] -2016 [51] -Human (Liver failure) Hepatic function 2013 [52] Rabbit -Rabbit Remodeling 2011 [53] BM-MSCs/HSCs Human -Human (EPP) Engraftment 2010 [54] BM-MSC Human -Human (LC) Engraftment, hepatic function 2011 [55] -Rat (Wistar) Hepatic function 2014 [56] -Mouse (SCID) Engraftment, analysis of glucose 2017 [57] -Mouse (Pfp/Rag2 −/− ) Engraftment 2010 [58] Rhesus macaque -Mouse Hepatic function 2018 [59] Rat -Rat (SD) Hepatic function 2014 [60] BM-MNC-EPC Rat -Rat (SD) Remodeling 2012 [61] Liver-MSCs Human -Mouse (NOD/SCID) Engraftment, repopulation 2011 [62] AD-MSCs Human -Mouse (c57/B6) Analysis of IRI 2014 [63] Mouse -Mouse (Swiss CD1) Repopulation 2012 [64] AD-MSC-Hep Mouse -Mouse (C57BL/6) Engraftment 2015 [65] CD34+ cells Human -Human (LC) Hepatic function 2015 [66] ESCs-Hep Mouse -Mouse (BALB/c) Engraftment, hepatic function 2012 [67] iPSC-Hep Human Organoid Mouse (Alb-Tk-NOG) Survival extension, hepatic function 2017 [68] Organoid Mouse (NOD/SCID) Engraftment 2013 [69] Mouse -Mouse (Fah-/-C57Bl/6) Engraftment 2010 [70] iMPC-Hep Human -Mouse (FRG) Engraftment 2014 [71] GPSCs-Hep Mouse -Mouse (Hfe-null) Engraftment 2015 [72] Liver stem cells Rat Organoid Rat (Fah −/− Il2rg −/− ) Engraftment, hepatic function 2016 [73] " patients with errors of metabolism and acute-on-chronic liver failure (ACLF). Nevertheless, the use of human hepatocytes has limitations including limited organ availability, limited cell proliferation, loss of function, and risk for immune rejection [101, 102] . Previous studies have explored the application of not only hepatocytes but other cell sources as well. Xue et al [103] performed a meta-analysis of cell transplantation for ACLF including nine RCTs. In this report, UC-MSCs and bone marrow-derived MSCs (BM-MSCs) were used as the cell source, which improved the survival period and liver function. MSCs, especially BM-MSCs, have shown immunomodulatory and antifibrotic effects in other organ systems, and MSC transplantation has shown positive results in the treatment of liver fibrosis [104, 105] . We also found 2 reports of hematopoietic stem cell transplantation, but they were relatively less applied than UC-MSCs and BM-MSCs.
Most importantly, MSCs can secure more sources than hepatocytes, but the problem of cell quality still remains. As a stem cell therapy, iPSCs attract considerable attention in the field of transplantation. iPSCs were established from adult fibroblasts by introducing dierent transcription factors [106] . They overcame the ethical aspects of ESCs and have the self-renewal properties and pluripotency, the ability to differentiate into various somatic cells, including hepatocytes [107] .
HLCs derived from human iPSCs have been researched as a potential alternative to hepatocytes for cell therapy, disease models, and evaluating drugs [108, 109] Takebe et al [3] succeeded in creating a liver bud with iPSCs derived HLCs. This study demonstrated a three-dimensional liver bud produced by co-culturing with Human Umbilical Vein Endothelial Cells and MSCs was able to improve the liver function of recipient following transplantation.
A 3 dimensional (3D) culture is effective for hepatocyte functionality [110] , and using a method combining iPSCs and 3D culture may eventually assure high cell quality and quantity.
Nevertheless, because of potential tumorigenicity, the risks of developing teratomas, and the lack of long-term safety and ecacy, 3D cultures and iPSCs have not been clinically applied yet [111, 112] . In our search, we did not find many studies elucidating the in vivo application of iPSCs.
Cell transplantation also suffers from these above-mentioned challenges. Moreover, in the recent years, in vitro expansion of human hepatocytes has been explored [113] to overcome the challenges with iPSCs. The improvements in these approaches may lead to the development of alternative therapies. Baboon Survival extension 2018 [5] ; 2017 [14] ; 2014 [75] ; 2012 [76] ; 2010 [77] Analysis of thrombotic microangiopathy 2016 [78] Analysis of platelet 2014 [79] Analysis of rejection 2012 [80] Platelet aggregation 2012 [81] Analysis of coagulopathy 2012 [82] Hepatic function 2010 [83] Pig Baboon Analysis of immunoglobulin 2018 [84] Rabbit Porcine, rabbit Analysis of IgG 2012 [85] GTKO: Alpha 1-3 galactosyltransferase gene knockout; IgG: Immunoglobulin G.
Xeno-organ transplantation
The first successful animal-to-animal liver xenotransplantation was reported in 1968 [114] . Because of the development of immunosuppressive drugs, various studies were conducted that targeted the applicability of harvested organs from other species. Among animals, pigs were proved as useful in terms of size and rejection strength; therefore, genetically modified porcine organs hold enormous potential for this purpose. Although the cornea and skin of pig have been clinically applied, for OLT, the survival period is so short that liver xenotransplantation could not been applied clinically. To solve the problem of severe rejection, GT-KO pig was developed, intending to reduce the risk of GVHD [115] . The recent development of CRISPR/Cas9 has made this animal model more suitable [116] . Regarding xenotransplantation, 12 of 14 articles in our search used GT-KO pigs. Shah et al [14] reported that a human prothrombin-concentrate complex and immunosuppression was used on GT-KO pigs and that the survival was improved. Even then, it is necessary to improve physiological problems such as rejection, coagulation factors, and complementary species specific for application in humans.
Scaffold-based transplantation
Regarding rejection and infection, decellularization of tissue is an attractive method. Decellularization of tissues and even whole organs represents a novel approach for developing perfusable extracellular matrix (ECM)-derived scaffolds with preserved vascular integrity. Decellularized tissue is rarely rejected and is used for tissue reconstruction as scaffold material [117] . This decellularized scaffold is transplanted orthotopically or ectopically. The decellularization of whole organ was first introduced by Ott et al [118] in 2008 with the aim of developing acellular hearts from mice. Bovine heart valves and corneas or those from pigs have already been commercialized and clinically applied [119] . In recent years, research has been conducted on human liver and hepatocytes. Mazza et al [2] reported in 2015 that human liver was decellularized and re-cellularized with a liver cell line to create engineered livers.
KaKabadze et al [15] engrafted sheep liver cells on decellularized human placenta and transplanted them into sheep that underwent partial hepatectomy. Human placenta was considered as an attractive source because it has a well-developed vascular network and ECM for tissue engineering. Moreover, it is usually discarded and widely available.
In addition, many articles exhibited the application of decellularized tissues and biomaterial-based scaffold.
As biomaterials, natural biomaterials are applied such as collagen and hyaluronic acid, and synthetic materials such as polymers based on polylactic acid and polyglycolic acid, among others [16] [17] [18] . Previous reports show that after transplanting these scaffolds, the liver function in recipients improved [19] [20] [21] .
More recently, bio-printed scaffolds have been developed that mimic the tissue using these biomaterials [120] . However, they have problems of vascularization for tissue engraftment and repopulation, which warrant further research.
Meanwhile, scaffold-based transplantation with an ECM was proven effective, and further research is underway with an aim to select ideal cells for humans [119] .
iPSCs and few other cell sources are seeded and cultured in decellularized tissue and other scaffolds such that tissue regeneration in vitro can be performed. Therefore, [2] Porcine Rat (F344) Immunogenicity 2013 [86] Porcine Immunogenicity 2013 [87] Porcine Engraftment 2012 [88] Sheep, rat Sheep, rat Engraftment 2015 [89] Rat Hepatocytes (rat), BM-MSCs (Rat)
Rat (Lewis) Engraftment 2014 [90] Hepatocytes (rat) Rat (Lewis) Engraftment, Hepatic function 2010 [91] , 2011 [92] Mouse Hematopoietic progenitor cells (mouse)
Mouse ( [17] Polyethylene glycol hydrogels Hepatocytes (rat) Mouse (Nude) Engraftment 2015 [20] Microbeads Hepatocytes (rat) Rat (SD) Hepatic function 2014 [96] Poly-L-glycolic acid Hepatocytes (mouse) Mouse (NOD/SCID) Engraftment 2014 [21] Hyaluronan hydrogels Hepatic stem cells (human)
Mouse (Athymic nude) Engraftment 2013 [97] Apatite-fiber scaffold Hepatocytes ( further research should aim to solve this problem for actualizing its application clinically.
Conclusion and future perspectives
Our study summarized alternative therapies for OLT. Alternative therapies have been deeply researched, particularly xeno-organ, scaffold-based, and cell transplantations. Clinically, only cell transplantation with hepatocytes or MSCs has been applied. Scaffold-based transplantation is a comprehensive treatment that combines xenoorgan and cell transplantations. Future research on the clinical application of scaffoldbased transplantation is expected. [2] Porcine 16 [5, 14, [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [86] [87] [88] Sheep 1 [89] Rabbit 1 [85] Rat 4 [89] [90] [91] [92] Mouse 2 [93, 94] Hepatocytes (adult) Total 31
Human 10 [13, 16, [22] [23] [24] [25] [26] [27] [28] [29] Rat 14 [17, 20, [30] [31] [32] [33] [34] [35] [36] [37] [90] [91] [92] 96] Mouse 7 [21, [38] [39] [40] [41] [42] 98] Hepatocytes (fetal) Total 3
Rat 2 [18, 43] Mouse 1 [44] Liver cells Total 3
Human 1 [19] Sheep 1 [15] Rabbit 1 [45] MSCs (umbilical cord) Human 3 [29, 48, 49] MSCs (bone marrow) Total 15
Human 9 [50] [51] [52] [54] [55] [56] [57] [58] 99] Macaques 1 [59] Rabbit 1 [53] Rat 3 [60, 61, 90] Mouse 1 [94] MSCs (Adipose) Total 4
Human 2 [17, 63] Mouse 2 [64, 65] MSCs (liver) Human 1 [62] Hematopoietic stem cells Human 2 [54, 66] ESCs Mouse 1 [67] iPSCs Rat 1 [73] MSCs: Mesenchymal stem cells; ESCs: Embryonic stem cells; iPSCs: Induced pluripotent stem cells; GPSCs: Germ line cell-derived pluripotent stem cells.
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Research background
Orthotopic liver transplantation (OLT) is the only treatment for end-stage liver failure; however, the shortage of donor organs limits its application. To overcome this problem, many researchers have attempted to develop alternatives to OLT.
Research motivation
There are several reports of alternative therapies. Nevertheless, no study has comprehensively analyzed these therapies from varying perspectives.
therapies for OLT and to support future research.
Research methods
A systematic review was performed by searching the PubMed, Cochrane Library and EMBASE databases for studies concerning alternative transplantation therapy for OLT. We used the following MeSH terms: "liver transplantation", "cell", "differentiation", "organoid", and "xenotransplantation". Various types of studies were retrieved for full-text evaluation. Of these, we selected articles involving in vivo transplantation.
Research results
A total of 89 studies were selected. There are three principle forms of treatment: Xeno-organ transplantation (14 articles), scaffold-based transplantation (22 articles), and cell transplantation (53 articles). Various types of sources for transplantation were discussed: Organ liver, 25 articles; adult hepatocytes, 31 articles; mesenchymal stem cells (MSCs), 25 articles; induced pluripotent stem cells, three articles and other sources. Clinical applications were discussed only for cell transplantation (12 studies; four studies using hepatocytes, five studies using umbilical cordderived MSCs, three studies using bone marrow-derived MSCs, and two studies using hematopoietic stem cells).
Research conclusions
This systematic review summarized alternative therapies for OLT from varying perspectives. Alternative therapies have been deeply researched, particularly xeno-organ, scaffold-based, and cell transplantation. Clinically, only cell transplantation with hepatocytes and MSCs have been applied. Scaffold-based transplantation is a comprehensive treatment that combines xeno-organ and cell transplantations. Future research on the clinical application of scaffold-based transplantation is expected.
Research perspectives
This systematic review describes the current status of alternative therapy for OLT in end-stage liver failure. Further studies are needed for clinical applications in the future.
